Xeris Biopharma Holdings (XERS) Invested Capital (2020 - 2026)

Xeris Biopharma Holdings has reported Invested Capital for 7 years, with the latest figure at $234.2 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 20.35% year-over-year to $234.2 million; the trailing twelve-month figure through Mar 2026 stood at $234.2 million (up 20.35% YoY), and the FY2025 full-year result was $234.0 million, up 15.57% from the prior year.
• Invested Capital for Q1 2026 stood at $234.2 million, roughly flat from $234.0 million in the prior quarter.
• The five-year high for Invested Capital was $234.2 million in Q1 2026, with the low at $184.2 million in Q4 2023.
• Historically, Invested Capital has averaged $210.2 million across 5 years, with a median of $211.2 million in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital surged 966.02% — and 2023, when it decreased 20.71%.
• Xeris Biopharma Holdings' Invested Capital stood at $232.3 million in 2022, then declined by 20.71% to $184.2 million in 2023, then advanced by 9.96% to $202.5 million in 2024, then grew by 15.57% to $234.0 million in 2025, then advanced by 0.09% to $234.2 million in 2026.
• The last three Invested Capital figures came in at $234.2 million (Q1 2026), $234.0 million (Q4 2025), and $218.6 million (Q3 2025), per Business Quant data.